Break Free, Stay Free
Next-generation solutions for nicotine dependency.
The first once-daily oral medication and advanced medical device for smoking cessation.
Oral Once-Daily Smoking Cessation SPX-0152
Clinical Trials: 2026
Electronic Delivery of Inhaled Therapeutics (EDIT) Platform
NIH SBIR Phase I
Smoking accounts for 1 in 5 deaths per year.
In the U.S., 28.3 million Americans smoke cigarettes, 49.2 million people use tobacco products, and vaping is projected to grow 20% each year.
Smoking is the leading cause of preventible death, and in 2018 was estimated by the CDC to cost the U.S. $600 billion.
Yet there has not been a sustainable FDA-approved therapy in over 19 years.
Our Approach
At SpaceRx, we’re tackling the two biggest obstacles to quitting smoking: underperforming medications and deeply ingrained habits.
Most treatments fall short because they fail to address both the physical and psychological sides of addiction.
We’re developing next-generation pharmaceuticals that work with the body to disrupt nicotine dependence at its core, to make quitting not just possible—but sustainable.
News & Events
Related Topics
Smoking Cessation And Nicotine De-Addiction Market Impact of AI and Automation
Supported By
We’re proud to have the continued support of NIH NIDA through multiple SBIR/STTR awards, which are helping drive both projects toward meaningful, real-world impact.